Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Bardy Diagnostics, founded in 2013 and headquartered in Bellevue, Washington, is a leading provider of advanced ambulatory electrocardiogram monitoring solutions. The company specializes in P-wave centric electrocardiogram patch monitors designed for extended wear, offering healthcare professionals tools to enhance patient cardiac care and streamline clinical workflows. Bardy Diagnostics has made significant strides in the medical technology sector, raising a total of $92.93 million in funding since its inception.
In August 2021, Bardy Diagnostics was acquired by Hillrom, marking a significant milestone in the company's journey. This acquisition has likely impacted any potential plans for an initial public offering (IPO) that Bardy Diagnostics may have had. As a result of the acquisition, it is unlikely that Bardy Diagnostics will pursue an IPO as an independent entity.
Given the current circumstances, we do not have any concrete information or reports regarding Bardy Diagnostics' IPO prospects. The company's future direction and potential public offering plans are now closely tied to Hillrom's strategic decisions and market positioning. Investors interested in gaining exposure to Bardy Diagnostics' technology and market potential may need to consider Hillrom's publicly traded stock instead.
It's important to note that the medical technology sector continues to evolve rapidly, and companies like Bardy Diagnostics play a crucial role in advancing cardiac care. While an IPO may not be on the horizon for Bardy Diagnostics itself, the company's innovative solutions continue to contribute to the broader healthcare industry.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Bardy Diagnostics' IPO prospects remain uncertain, investors eager to explore opportunities in the medical technology sector don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the healthcare and medical device industries, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of innovative companies like Bardy Diagnostics before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
